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Abstract: The hypoxic tumor microenvironment plays significant roles in tumor cell metabolism 
and survival, tumor growth, and progression. Hypoxia modulates target genes in target cells 
mainly through an oxygen-sensing signaling pathway mediated by hypoxia-inducible factor of 
transcription factors. As a result, hypoxic tumor cells are resistant to conventional therapeutics 
such as radiation and chemotherapy. Oncolytic virotherapy may be a promising novel therapeutic 
for hypoxic cancer. Some oncolytic viruses are better adapted than others to the hypoxic tumor 
environment. Replication of adenoviruses from both groups B and C is inhibited, yet replication 
of herpes simplex virus is enhanced. Hypoxia seems to exert little or no effect on the replication 
of other oncolytic viruses. Vaccinia virus displayed increased cytotoxicity in some hypoxic 
cancer cells even though viral protein synthesis and transgene expression were not affected. 
Vesicular stomatitis virus replicated to similar levels in both hypoxic and normoxic conditions, 
and is effective for killing hypoxic cancer cells. However, vesicular stomatitis virus and reovirus, 
but not encephalomyocarditis virus, are sensitive to elevated levels of hypoxia-inducible 
factor-1α in renal cancer cells with the loss of von Hippel–Lindau tumor suppressor protein, 
because elevated hypoxia-inducible factor activity confers dramatically enhanced resistance to 
cytotoxicity mediated by vesicular stomatitis virus or reovirus. A variety of hypoxia-selective 
and tumor-type-specific oncolytic adenoviruses, generated by incorporating hypoxia-responsive 
elements into synthetic promoters to control essential genes for viral replication or therapeutic 
genes, have been shown to be safe and efficacious. Hypoxic tumor-homing macrophages can 
function effectively as carrier cells to deliver an oncolytic adenovirus to the hypoxic/necrotic 
areas of the tumor. It is envisioned that further improved oncolytic viruses will be highly 
effective against hypoxic tumor, especially when combined with other therapeutic regimens 
such as immunotherapy, radiation therapy, and/or chemotherapy.
Keywords: hypoxia, oncolytic virus, viral replication, viral spread, oncolysis, HIF, macrophage, 
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Introduction
The utilization of viruses for cancer treatment has garnered interest for several decades.1 
These viruses, either by innate properties per se or modified via genetic engineering, 
possess the ability to infect and/or replicate exclusively in cancer cells, allowing 
normal cells to remain unharmed.2–4 As the first-generation oncolytic viruses (OVs) 
have been tested in clinical trials, novel genetic engineering approaches have permitted 
the design of the next generation of recombinant viruses; these OVs demonstrate 
increased  oncolytic potency in neoplastic tissue without compromising safety in animal 
models.2,5 In both preclinical models and clinical trials, OVs have often been utilized 
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in combination with radiation therapy, classic chemothera-
peutics, prodrug therapy, or immunotherapy in order to 
achieve better efficacy.6–10
Since the first genetically engineered virus, a herpes sim-
plex virus (HSV), was explored as an OV, hundreds of other 
engineered viruses or naturally selected viruses have been 
studied in tumor models in preclinical studies. Several of  these 
OVs have been examined in phases I–III clinical trials (for a 
list of OVs in clinical trials, see the table by Rowan, 2010).11 
OVs expressing the cytokine granulocyte-macrophage colony-
stimulating factor have shown great promise. OncoVEX GM-
CSF (cytokine granulocyte-macrophage  colony-stimulating 
factor) has been tested in phase I/II trials.12 A prospective, 
randomized phase III clinical trial in patients with unresectable 
stages III and IV melanoma is being completed.13 An onco-
lytic poxvirus expressing cytokine granulocyte-macrophage 
colony-stimulating  factor, JX-594, is genetically engineered 
for replication and transgene expression in cancer cells har-
boring an activated epidermal growth factor receptor/Ras 
pathway, followed by cell lysis and anticancer immunity. The 
virus, either alone or in combination with sorafenib, a small 
molecule inhibitor of B-Raf and vascular endothelial growth 
factor (VEGF) receptor, was well-tolerated and displayed 
objective tumor response in a small number of patients with 
hepatocellular carcinoma.14 In a recent study, Breitbach et al 
showed in a clinical trial that JX-594 selectively infects, 
replicates, and expresses transgene products in cancer tis-
sue after intravenous infusion in a dose-related fashion in 
human cancer patients.15 China approved the world’s first 
OV (H101) for cancer treatment in 2005, showcasing the 
potential of OVs as a new class of pharmaceutical drugs for 
cancer patients.16
Tumor microenvironment (TME) plays an important role 
in dictating not only the replication but also oncolytic effects 
of OVs.3,17–19 Hypoxia is one of the hallmarks of solid tumor. 
The interplay of hypoxic TME and OV is a key factor deter-
mining not only the outcome of viral replication, spread, and 
potential oncolysis in a specific tumor but also the overall 
efficacy of oncolytic virotherapy.3,17–19 The field of oncolytic 
virotherapy for hypoxic tumor was reviewed by Hay in 2005.20 
Here, the focus will be on recent new and exciting progress 
in the field and a discussion of future directions for develop-
ing OVs in the setting of treating hypoxic tumors.
Overview of the biological 
properties of OVs
Ideally, an OV is a virus that preferentially infects and 
lyses cancer cells while leaving normal cells unharmed. 
These viruses have been explored to treat cancer, both by 
direct destruction of the tumor cells, and, if modified, as vectors 
enabling genes expressing anticancer proteins to be delivered 
specifically to the tumor site.1–3 In general an OV is able to 
attach to and infect the tumor cells, replicate in these tumor 
cells, and “lyse” them, thereby releasing progeny virus into the 
surrounding TME and infecting neighboring tumor cells. This 
process would prime the host immune system and generate 
specific immunity against the tumor cells as well as the virus. 
Several recent reports have presented evidence of synergistic 
effects between direct virus-mediated oncolysis and the activa-
tion of specific antitumor immune responses.21,22 In the clinical 
setting, more rational, potentially synergistic combination 
strategies are being tested.23 These combination strategies offer 
an exciting outlook for the future of cancer virotherapy.
There are some naturally occurring OVs that selectively 
kill tumor cells while leaving normal cells unharmed.24 
Examples of these OVs include measles virus, Newcastle 
disease virus, reovirus, and vesicular stomatitis virus 
(VSV), most of which are ribonucleic acid (RNA) viruses. 
The mechanisms of tumor cell selectivity appear to be that 
these viruses are able to exploit differences in the biology 
between tumor cells and their normal counterparts that arise 
during the transformation into a cancer cell.24 For example, 
the selectivity of VSV strains and myxoma virus is mediated 
by tumor cell-specific defects in interferon responsiveness 
or innate immunity.24–27 Instead, the oncolytic specificity of 
Newcastle disease virus is selected for apoptosis-resistant 
cells, not for defect of interferon responsiveness as believed 
previously.28
Most OVs are generated via genetic engineering for 
enhanced tumor selectivity. Normally, viruses will infect nor-
mal cells. For adenoviruses (Ads), this is via an oral or nasal 
route of entry and involves the epithelial lining of the nose, 
throat, and/or gut resulting in a respiratory and/or gastroin-
testinal infection. When used as an agent in cancer therapy, 
the objective is to develop recombinant Ads that selectively 
infect a vastly different set of cells, namely, transformed 
epithelial cells and tumor-associated endothelium located in 
distinct locations throughout the body, most of which are not 
normally seen during the typical Ad infection. Researchers 
must develop OVs that efficiently and selectively replicate 
in, and kill, cancer cells to which they would not normally 
be exposed. An additional requirement is that these OVs 
can adapt to hypoxic tumor cells for survival, to proliferate, 
and to exert their potential for oncolysis. There are at least 
two methodologies to develop OVs targeting hypoxic tumor 
environment. The primary one is based on rational design 
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by genetic engineering. An alternative approach employs 
directed evolution as a means of producing highly selective 
and potent anticancer viruses.29 Using this “directed evo-
lution” methodology, Bauzan and Hermiston generated 
ColoAd1, a novel chimeric OV.29 In vitro, this virus dem-
onstrated a .2 log increase in both potency and selectivity 
when compared to ONYX-015 on colon cancer cells.30 This 
approach may be applied to generate other novel and potent 
OVs targeting hypoxic tumor cells.
Overview of the tumor hypoxic 
environment and why current 
therapies do not work effectively
Hanahan and Weinberg have recently made a new summary 
of cancer hallmarks.31 Adding to the six classic hallmarks are 
two emerging hallmarks: reprogramming of energy metabo-
lism and evading immune destruction. The key physical and 
chemical properties of TME often include hypoxia, nutrient 
deprivation, acidosis, and aberrant stroma.32,33 The TME is 
being increasingly recognized as an important determinant 
of tumor progression as well as of therapeutic response.34 
The TME and its tumor-stromal interactions are capable of 
altering the delivery and effectiveness of therapeutics into 
the tumor, including oncolytic virotherapy.17–19,34
What are hypoxia and tumor hypoxia? As stated by 
Hockel and Vaupel,35 biochemists may define hypoxia as 
molecular oxygen-limited electron transport. Physiologists 
and clinicians may define hypoxia as a state of reduced 
oxygen availability or pressures below critical thresholds, 
thus hindering or abolishing the function of organs, tissues, 
or cells. In solid tumors, oxygen delivery to the respiring 
neoplastic and stromal cells is frequently reduced or even 
abolished by deteriorating diffusion geometry, severe struc-
tural abnormalities of tumor microvessels, and disturbed 
microcirculation. As a result, areas with very low oxygen par-
tial pressures exist in solid tumors, occurring either acutely 
or chronically. By definition, there are two types of hypoxia 
in tumor: chronic hypoxia and intermittent hypoxia. Chronic 
hypoxia refers to the imbalance between oxygen delivery 
and oxygen consumption, which exists in regions of tumors 
beyond the diffusion distance of oxygen. The disorganized 
tumor neovasculature is generally claimed as the common 
denominator of the above causes of deficit in oxygen supply. 
The other form, acute or intermittent hypoxia, is a ubiquitous 
process occurring within most solid tumors. It can exist at a 
distance (even more than 100 µM) from a tumor  microvessel. 
Fluctuations in pressure of oxygen of approximately 
20 mmHg can occur with periodicities of minutes to hours 
and even days.36,37 The major phenotypic shift associated with 
chronic hypoxia is tumor cell resistance to chemotherapy and 
radiotherapy and more invasive and metastatic features. In 
contrast, acute hypoxia may exert more effects on the phe-
notype of endothelial cells lining tumor blood vessels, which 
may have significant therapeutic implications. Acute hypoxia 
may permit resistance to treatment and thereby affects the 
survival of hundreds of tumor cells.36
Three main oxygen-sensing pathways promote hypoxia 
tolerance by regulating gene transcription and messenger 
RNA translation in cells exposed to hypoxia. It has long been 
known that transcription factors hypoxia-inducible factor-1α 
(HIF-1α) and HIF-2α play critical roles in cellular response 
to hypoxia.38–40 The most characterized molecular response 
to hypoxia is the stabilization and activation of HIF-1. 
HIF-1 is a heterodimer composed of the HIF-1α subunit and 
the HIF-1β subunit. During hypoxia, a shift from aerobic 
metabolism to glycolytic metabolism is mediated in a large 
part by HIF-1, via upregulation of various metabolic genes, 
such as glucose transporters, aldolase, lactate dehydrogenase, 
and pyruvate kinase. Even though both subunits of HIF-1 
are constitutively expressed, HIF-1α is rapidly degraded in 
the presence of cellular oxygen via the ubiquitin-mediated 
proteasome pathway. Recently, two other oxygen-sensitive 
signaling pathways have also been implicated: signaling 
via the mammalian target of rapamycin (mTOR) kinase and 
through activation of the unfolded protein response.41 Even 
though these signaling pathways function independently in 
response to hypoxia, evidence has accumulated that HIF-, 
mTOR-, and unfolded protein response-dependent responses 
to hypoxia act in an integrated way, influencing each other and 
common downstream pathways that affect gene expression, 
metabolism, cell survival, tumorigenesis, and tumor growth.41 
Some recent studies have linked mTOR signal and HIF-1α 
to CD133 expression, a cancer stem cell marker in cancer 
cells. This might lead to insights into the involvement of the 
mTOR signal and oxygen-sensing intracellular pathways in 
the maintenance of stemness in cancer stem cells.42–46
The other response to hypoxia in mammalian cells is a G1 
cell cycle arrest, in addition to adaptive metabolic changes. 
Early work showed that hypoxia inhibits G1/S transition 
through regulation of p27 expression.47 However, later work 
showed the real mechanisms are much more complex.48 The 
hypoxia-induced replication arrest initiates a DNA damage 
response that includes both ataxia telangiectasia mutated-
related and ataxia telangiectasia mutated plus Rad3-related 
mediated signaling.49 Although G1 cell arrest in response to 
hypoxia is observed in normal cells and some cancer cells, 
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little or no effect on S phase has been reported in cells with 
disrupted HIF-1α signaling and in some cancer cells. 
G1 arrest of tumor cells in hypoxic conditions may not be 
critical to limit viral replication for at least some viruses. 
In fact, hypoxia may induce DNA overreplication in tumor 
cells.50 DNA replication can be blocked by hypoxia, but only 
at nonphysiological levels of ,0.1% oxygen.20
Hypoxia promotes immune suppression in the TME via 
multiple mechanisms. It modulates both the innate immunity 
and adaptive immunity. Hypoxia links to the innate immu-
nity and inflammation via nuclear factor-κB (NF-κB).51 
 Monocytes are continually recruited into tumors, differentiate 
into tumor-associated macrophages, and then accumulate in 
the hypoxic/necrotic areas. Hypoxia via HIF-1α dramatically 
alters the function of myeloid-derived suppressor cells in 
the TME and redirects their differentiation toward tumor-
 associated macrophages.52 These macrophages exposed 
to hypoxia upregulate expression of HIF-1α and HIF-2α, 
which then bind to hypoxic response elements (HRE) 
within the promoters of multiple tumor-promoting and 
adaptive genes to activate their expression.53 In a recent 
study, the authors showed that HIF-2α modulated mac-
rophage migration by regulating the expression of the 
cytokine M-CSF receptor and chemokine (C-X-C motif) 
receptor 4,54 receptors important for tumor cell prolif-
eration, invasion, and metastasis.55 In another study, tar-
geted deletion of HIF-1α in macrophages in a progressive 
murine model of breast cancer resulted in reduced tumor 
growth, although VEGF-A levels and vascularization were 
unchanged.56 The authors found that hypoxia powerfully 
augmented macrophage-mediated T-cell suppression in vitro 
via HIF-1α expressed from macrophages.56 These responses 
may help explain the correlation between high numbers of 
tumor-associated macrophages and poor prognosis in various 
forms of cancer and offer a potential target for therapy.57–59
Hypoxia can exert direct effects on adaptive immunity. 
It drives the extracellular accumulation of adenosine in the 
local TME. The adenosine triggers the immunosuppressive 
signaling via intracellular cyclic adenosine monophosphate-
elevating A2A adenosine receptors on antitumor T cells.60 
In addition, the activated antitumor T cells in hypoxic TME 
could be inhibited by elevated levels of immunosuppressive 
HIF-1α. Recent studies have demonstrated that hypoxia 
leads to a decrease in cytotoxic T lymphocyte-mediated 
tumor cell lysis via the cooperative induction of HIF-1α 
and the  phosphorylation of signal transducer and activator 
of transcription 3, and the induction of NANOG in target 
cancer cells.61,62 Another mechanism is that tumor hypoxia also 
promotes the recruitment of regulatory T cells through induction 
of expression of chemokine (C-C motif) ligand 28, which in 
turn promotes tumor tolerance and angiogenesis.63 In summary, 
hypoxia-induced changes lead to the diminished innate and adap-
tive immunity against cancer. These results may help explain the 
poor responses of hypoxic cancer to immunotherapy.
Hypoxia may also lead to resistance to ionizing radiation 
and chemotherapy by depriving tumor cells of the oxygen 
essential for the cytotoxic activities of these agents. Hypoxia 
may also reduce tumor sensitivity to radiation therapy and 
chemotherapy through one or more indirect mechanisms that 
include proteomic and genomic changes.64,65 Tumor hypoxia 
influences the outcome of cancer radiotherapy. Oxygen is 
a potent chemical radiosensitizer. Oxygen is an extremely 
electron-affinic molecule that participates in the chemical 
reactions that lead to the production of DNA damage after the 
absorption of energy from ionizing radiation. Cells that are 
anoxic during irradiation are about three times more resistant 
to radiation than cells that are well oxygenated at the time 
of irradiation.66 Because the underlying chemical reactions 
are essentially complete within a few milliseconds after 
irradiation, oxygen must only be present during irradiation to 
produce full radiosensitization. Resistance of hypoxic tumor 
to chemotherapy comes from multiple mechanisms. Three 
basic categories underlie chemotherapy failure: inadequate 
pharmacokinetic properties of the drug, tumor cell intrinsic 
factors (eg, drug efflux pumps), and tumor cell extrinsic con-
ditions which are characterized by such hostile conditions as 
hypoxia, acidosis, nutrient starvation, and increased intersti-
tial pressure present in the TME.67 For example, Rohwer and 
colleagues recently identified HIF-1α as a potent regulator of 
p53 and NF-κB activity under conditions of genotoxic stress 
derived from chemotherapy in gastric cancer.68 In summary, 
multiple molecular mechanisms involving hypoxia contribute 
to resistance to conventional therapeutics. Despite recent 
advancement in the knowledge regarding tumor hypoxia, 
there are still major questions to be addressed if the long-
standing goal of exploiting tumor hypoxia is to be realized. 
To address these questions, investigators have studied thera-
peutic modalities including prodrugs activated by hypoxia, 
hypoxia-specific gene therapy, targeting transcription factor 
HIF-1, and tumor metabolism.40,64,69
The effects of hypoxia and leaky 
vasculature on the access and 
spread of OVs
Many OVs are large particles, thus they suffer from 
 inefficient extravasations from tumor blood vessels after 
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systemic delivery. Their ability to reach cancer cells is an 
important consideration in achieving specific oncolytic 
targeting and potential viral replication. Hypoxia upregulates 
the expression of vascular permeability factor, VEGF, thus 
enhancing the vascular permeability. This should promote 
both extravasation of input OV into tumor cells and spread-
ing of progeny OVs to neighboring tumor cells. However, 
increased vascular permeability and inflammation will also 
promote infiltration of immune cells that will prematurely clear 
the viruses resulting in reduction of therapeutic efficacy.
A number of research laboratories have come up with strate-
gies to modulate tumor vascular leakiness in order to enhance the 
efficiency of specific delivery of OVs to tumor cells.  Kurozumi 
and colleagues investigated OV therapy-induced changes in 
tumor blood vessels and the impact of modulating tumor vas-
culature on the efficacy of OV therapy.34 They found that OV 
treatment increased tumor vascular permeability, host leukocyte 
infiltration into tumors, and intratumoral expression of inflam-
matory cytokine genes, including interferon-γ.  Pretreatment 
with cyclic Arg-Gly-Asp peptide, which is angiostatic, reduced 
tumor vascular permeability, leukocyte infiltration, and 
interferon-γ protein levels, increased viral titers in tumor tis-
sue, and had longer median survival.34 Vile and associates have 
shown that antiangiogenic cancer therapy combined with onco-
lytic virotherapy leads to regression of established tumors in 
mice.70 They initially hypothesized that transient destabilization 
of tumor vasculature by VEGF
165
 may facilitate intratumoral 
delivery of OVs. It turned out that, although VEGF
165
 enhanced 
vascular leakage, therapeutic effects derived mainly from 
VEGF
165
-mediated stimulation of endothelial cells transiently 
to support viral replication. Appropriately timed systemic virus 
delivery led to viral replication in and lysis of tumor-associated 
endothelial cells and innate immune-mediated antivascular 
effects with subsequent vascular collapse. In another study, 
Breitbach et al showed that VSV directly infects and destroys 
tumor vasculature in vivo but leaves normal vasculature intact. 
VSV replicates in tumor neovasculature and spreads within 
the tumor mass, initiating an inflammatory reaction including 
a neutrophil-dependent initiation of microclots within tumor 
blood vessels.71 Tseng et al showed that VEGF and/or metro-
nomic chemotherapy regimens could indeed enhance tumor 
vascular permeability and directly enhances oncolytic Sindbis 
virus targeting in tumor models.72
The effects of hypoxia on the 
replication and oncolysis of OVs
The objective of all viruses is to infect target cells, replicate 
large numbers of progeny virions, and spread these progeny 
to initiate new rounds of infection. However, target organisms 
possess both systemic and cell-based defenses to limit virus 
infection, including immune and inflammatory processes 
and the execution or suicide of infected cells.73 Protective 
mechanisms (such as induction of apoptosis) are in place in 
normal cells to prevent viral replication. In hypoxic cancer 
cells, the eventual success or failure of viral replication may 
depend on the interplay between adaptive processes that 
allow survival of tumor cells in hypoxia and cellular protec-
tive responses to inhibit viral replication. A major cellular 
response to stresses, such as hypoxia and viral infection, is 
the shutdown of protein synthesis. Hypoxia affects host cell 
translational machinery. Since all viruses depend on the host 
translational machinery to translate their own proteins, the 
hypoxic state of infected cells may play a critical role in the 
viral life cycle, replication, and thus the success of oncolytic 
virotherapy.20
The rationale is to treat the hypoxic tumor with an OV 
that can infect, replicate in, and lyse the hypoxic tumor cells. 
Alternatively, it is possible to make hypoxic tumor cells 
less hypoxic, or even normoxic, so that these “modified” 
tumor cells or tumor cells in the “modified” TME are now 
susceptible to infection, replication, and oncolysis by OVs. 
How inflammation induced by virus infection impacts on the 
TME is also an important issue. Breitbach et al showed that 
administration with VSV and vaccinia virus (VACV) resulted 
in a dramatic transcriptional activation of the proinflamma-
tory neutrophil chemoattractants (chemokine [C-X-C motif] 
ligand 1 and 5) and results in neutrophil attraction into the 
TME. The infiltrated neutrophils in turn contributed to acute 
reduction in tumor vasculature.74 Kirn et al showed that 
systemically administered VACV resulted in infection and 
subsequent destruction of tumor endothelial cells, which led 
to loss of tumor vascular density.75 Therefore, treatment with 
OVs may strengthen hypoxia in certain areas of the tumor.
Nine years ago, Hernandez-Alcoceba and colleagues 
pioneered the work of genetic engineering of an oncolytic 
Ad specifically for hypoxic tumor.76 Since then, many stud-
ies from a number of research laboratories have explored 
the properties of various OVs for hypoxic tumors. The 
following section summarizes the main findings regarding 
some representative OVs in the setting of hypoxic tumors. 
Some key effects of hypoxic conditions on selective OVs 
are listed in Table 1.
Ads
As just mentioned, the pioneering work on engineering 
an OV for hypoxic tumor was from Clarke and associates 
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in 2002.76 In that study, they designed an oncolytic Ad in 
which the early region 1A (E1A) gene was controlled by an 
HRE-containing promoter. The tight control of E1A expres-
sion correlated with the ability of the virus to replicate in 
and kill the human cancer cells that were maintained under 
hypoxic conditions.76 Subsequently, a number of groups have 
designed other hypoxia-dependent oncolytic Ads or utilized 
them to treat various types of cancer models.77–80 It is worth 
pointing out that such an OV could be highly efficient for 
the von Hippel–Lindau (VHL)-deficient tumor where HIF 
is constitutively elevated because of impaired ubiquitination 
of this transcription factor.78 In summary, these early stud-
ies demonstrated in principle that such genetically designed 
oncolytic Ads could be used, alone or in combination, to treat 
hypoxic solid tumors.
In 2005, two groups evaluated how hypoxia affects 
different aspects of Ad biology, including attachment and 
uptake, transgene expression, and replication, in cancer 
cells and primary normal cells.81,82 Both studies, one by Shen 
and Hermiston81 and the other by Pipiya et al,82 found that 
viral replication was compromised by hypoxic conditions. 
Hypoxia-induced reduction in E1A levels was mediated at 
the posttranscriptional level. The combination of reduced 
E1A protein and hypoxia-induced G1 arrest of cells may be 
responsible for the lack of efficient viral replication under 
hypoxic conditions. A further study using group B Ads 
(types 3 and 11p) showed that the lytic potential of these 
viruses is also compromised in a cell-dependent fashion. This 
study suggests that both group B and group C (Ad-5-based) 
Ads need to be modified in order to effectively treat hypoxic 
components of human tumors.83
Recently, investigators have returned to engineer sec-
ond generation HIF-activated oncolytic Ads that display 
improved replication, oncolytic, and antitumor efficacy.84 
These Ads are often armed with a transgene to further 
enhance its specificity and/or potency. A dual-regulated 
oncolytic Ad (CNHK500), in which human telomerase 
reverse transcriptase gene promoter controlling E1A gene and 
hypoxia-responsive promoter controlling E1B gene, showed 
increased safety with preserved antitumoral efficacy.85 In 
order to improve therapeutic efficacy, many such derived 
oncolytic Ads are armed with different classes of genes. One 
such study utilized a gene (wild type p53) for induction of 
apoptosis.86 Another group combined the hypoxia-targeted 
oncolytic Ad with genes encoding HSV thymidine kinase and 
bacterial nitroreductase for virus-directed enzyme prodrug 
therapy.87 Another group armed such an Ad with a gene 
for VEGF receptor 1-Ig and indeed it displayed a concur-
rent antiangiogenic effect in a tumor model.88 In another 
study, the gene encoding CD40 ligand was used due to its 
immunostimulatory activity.89 Post et al made an oncolytic 
Ad armed with an interleukin-4 gene (HYPR-Ad-IL4). The 
interleukin-4 cytokine was chosen for its ability to induce a 
strong host antitumor immune response and for its potential 
antiangiogenic activity.90 Finally, in order to enhance target-
ing specificity of the virus, a tumor-type-specific promoter 
could be used. One such virus utilized a modified human 
alpha-fetal protein gene promoter with multiple copies of 
HRE to stringently control the expression of E1A proteins, 
thus viral replication. This virus (Ad-HRE
12
/hAFP∆19) is a 
promising agent for hepatocellular carcinoma.91
HSV
Two studies have demonstrated the enhanced replication 
of oncolytic HSVs by hypoxia.92,93 Aghi et al showed that 
hypoxic glioblastoma U87 cells yielded 4% more wild-type 
HSV and 3.6-fold more oncolytic HSV G207 after 48 hours 
of infection when compared with normoxic cells.92 Reverse 
transcriptase polymerase chain reaction analysis confirmed 
a five-fold hypoxia-induced upregulation of GADD34 
Table 1 Effects of tumor hypoxia on oncolytic viruses
Oncolytic virus Replication efficiency Oncolysis Specific mechanisms References
Adenovirus Down Down 1. E1 A downregulation 
2. G1 cell growth arrest
Pipiya et al82 
Shen et al83
Hypoxia-dependent 
adenoviruses
Up Up Hypoxic response elements-
containing promoter to drive  
an essential gene for viral  
replication
Post et al90 
wang et al86
Herpes simplex virus-1 Up Up 1. Upregulation of GADD34 
2. Targeting p53 cancer cells
Aghi et al92 
Fasullo et al93
Vaccinia virus Similar Enhanced (in some  
hypoxic cells)
Unknown Hiley et al95
Vesicular stomatitis virus Similar Similar Connor et al96
Abbreviation: GADD34, growth arrest and DNA-damage inducible gene 34.
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(growth arrest and DNA-damage inducible gene 34) 
 messenger RNA, a factor complementing the γ34.5 gene 
deletion in G207. In vivo, G207 also exhibited enhanced 
replication in hypoxic environments, partly due to increased 
GADD34 expression in hypoxic cells.92 In the second study, 
Fasullo et al showed that another oncolytic HSV, R3616, 
which lacks the neurovirulence factor infected cell protein 
34.5 (ICP34.5), may target hypoxic breast cancer cells that 
lack functional p53.93 However, this conclusion was based 
solely on the comparison of viral yields from hypoxic and 
normoxic MDA-MB-231 (p53-) and MCF-7 (p53+) cells, and 
more data are needed to confirm that such enhanced viral rep-
lication depends only on p53 status. In summary, the unique 
tropism of oncolytic HSVs for hypoxic tumor environment 
contrasts with the hypoxia-mediated impairment of standard 
therapies; this enhances HSV’s appeal and efficacy in treating 
such hypoxic cancers as glioblastoma, pancreatic, cervical, 
and breast cancer.
Another strategy of targeting oncolytic HSV to hypoxic 
tumor, as done with Ads, is to exploit the differential activation 
of HIF-dependent gene expression in tumors versus normal 
tissue.94 Post and associates worked on such a strategy by 
placing an essential gene for viral replication, ICP4, under the 
regulation of an HIF-responsive promoter and then introduced 
into the thymidine kinase locus (U
L
23) of HSV d120, which 
contains partial deletions in the two endogenous ICP4 genes. 
Unexpectedly, HIF-HSV expressed ICP4 and induced tumor 
cell lysis at similar levels under normoxia and hypoxia. They 
found out that the lack of HIF-dependent ICP4 transgene 
expression by HIF-HSV was due to two factors: reversion 
of the ICP4 gene region to its wild-type configuration and 
increased HIF-transcriptional activity under normoxia when 
cells were infected with any strain of HSV-1. The findings 
have important implications for applications of this oncolytic 
HSV in cancer therapy and this genetic engineering strategy 
to other OVs targeting hypoxic tumor.
VACV
Hiley and colleagues explored the use of an oncolytic VACV 
for hypoxic tumors.95 They examined the Lister strain VACV 
in a panel of pancreatic cancer cells after exposure to normoxic 
or hypoxic conditions. Viral protein production and transgene 
expression were not affected by hypoxia. Interestingly, there 
was a 3.5-fold and 20-fold increase in viral cytotoxicity for 
CFPac1 and MiaPaca2 cell lines, respectively, in hypoxic 
conditions. Cytotoxicity was equivalent in the remaining 
cell lines. This study suggests that VACV is a promising 
vector for targeting pancreatic cancer and potentially other 
hypoxic tumor types.95 It would be of interest to determine 
the mechanisms of enhanced cytotoxicity of the virus in the 
two cell lines under hypoxia.
VSV
VSV, an RNA OV, is promising as its replication is naturally 
targeted to cancer cells with defects in innate immunity.25,26 
In an early study, Connor and colleagues demonstrated that 
VSV is capable of replication in cancer cells under hypoxic 
conditions.96 In hypoxia-stressed cells, VSV infection 
produced larger amounts of messenger RNA than under 
normoxic conditions. However, translation of these messenger 
RNAs was reduced at earlier times postinfection in hypoxia-
adapted cells than in normoxic cells. Surprisingly, at later 
times postinfection, the virus overcame a hypoxia-associated 
increase in alpha subunit of eukaryotic initiation factor-2 
phosphorylation and initial suppression of viral protein 
synthesis to produce large amounts of viral proteins. VSV 
infection caused the dephosphorylation of the eukaryotic 
translation initiation factor-4E and inhibited host translation 
similarly under both normoxic and hypoxic conditions. VSV 
progeny virus was produced at similar levels in both hypoxic 
and normoxic cells. As expected, virus infection induced 
classical cytopathic effects and apoptotic cell death. In vivo, 
VSV infected and replicated in hypoxic areas of tumors in 
nude mice. These results show for the first time that VSV has 
an inherent capacity for infecting and killing hypoxic cancer 
cells. This ability could represent a critical advantage over 
existing therapies in treating established tumors. Interestingly, 
HIF promotes the expression of the interferon-β and other 
genes with antiviral activity upon viral infection.97 It has been 
known that VHL tumor suppressor protein targets HIFs for 
oxygen-dependent proteolysis.98 Therefore, in VHL mutated 
renal cell carcinoma (RCC) cells, HIFs are highly elevated. 
As a result, VSV, and possibly other viruses as well, may not 
be suitable for treatment of RCC with mutated VHL tumor 
suppressor protein. In those VHL-/- tumor cells, elevated HIF 
activity induced by hypoxia confers dramatically enhanced 
resistance to VSV-mediated cytotoxicity.97
It is worth noting that VSV infection can generate 
complicated immune consequences. Intratumoral VSV 
induced a transforming growth factor-β-dependent 
suppressive activity mediated by CD11b(+)GR-1(+) cells 
that significantly inhibited both antigen-specific T-cell 
activation.99 VSV interferes with tumor dendritic cell 
function and blocks tumor antigen presentation.100 Therefore, 
adjustments need to be made if VSV treatment is combined 
with other types of immunotherapy regimens.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
77
The impact of hypoxia on oncolytic viruses
Virus Adaptation and Treatment 2011:3
Reovirus
Cho et al tested how oncolytic reovirus and its target cells 
would respond to hypoxia.101 They found that reovirus infec-
tion suppresses HIF-1α at the protein level, but not at the 
messenger RNA level, in colon cancer HCT116 cells under 
hypoxic conditions. This reduction of HIF-1α is independent 
of VHL or p53 because it took place in both VHL-/- renal 
carcinoma A498 and p53-/- HCT116 colorectal cancer 
cells. However, treatment with the inhibitor MG132 restored 
HIF-1α levels, suggesting that reovirus-induced HIF-1α 
decrease requires proteasomal activity. The authors pro-
posed to use reovirus together with an HIF-1α inhibitor as 
a potential therapeutic regimen against chemoresistant or 
radioresistant tumors that are hypoxic with increased levels 
of HIF-1α.101 As a result, there appears to be a functional 
similarity between reovirus and VSV in their sensitivity to 
elevated levels of HIF-1α.97,101
EMCV
Picornaviruses have been explored as OVs. Seneca Valley 
virus-001 is a novel naturally occurring replicating picorna-
virus with potent and selective tropism for neuroendocrine 
cancer cell types, including small cell lung cancer. It has 
been shown to be safe in patients.102
Encephalomyocarditis virus (EMCV) is another picorna-
virus that can function as an OV. As mentioned above, recent 
evidence has shown that HIF increases NF-κB-mediated anti-
apoptotic response in clear-cell RCC that commonly exhibits 
hyperactivation of HIF due to the loss of its principal negative 
regulator, VHL. In a recent study,103 Roos et al showed that 
EMCV challenge induces a strong NF-κB-dependent gene 
expression profile concomitant with a lack of interferon-
mediated antiviral response in VHL-null RCC. Established 
RCC cell lines and early-passage primary RCC cultured cells 
were acutely susceptible to EMCV replication and virulence. 
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Figure 1 Cotransduced (co-trans) monocyte-derived macrophages (MDMs) release green fluorescent protein (GFP)-expressing adenovirus in hypoxic prostate tumors. 
Human untransduced, singly transduced (singly trans), or cotransduced MDMs were injected systemically into athymic mice bearing LNCaP xenografts. At 48 hours later, 
tumor xenografts were removed, sectioned for immunofluorescence, or enzymatically dispersed for flow cytometry. Frozen sections were labeled with antibodies against 
pimonidazole (PIMO; white), human CD68 (red), and GFP (green). (A) white arrows show hypoxic macrophages. (B) Single cell suspensions were stained with antihuman 
CD14PE or propidium iodide and analyzed by flow cytometry. At right are representative fluorescent histograms from the same treatment groups. Data average ± standard 
deviation, n = 5 mice/group. 
Note: This figure is adapted and reprinted by permission from the American Association for Cancer Research: Muthana M, Giannoudis A, Scott SD, et al, Use of macrophages 
to target therapeutic adenovirus to human prostate tumors, Cancer Research, 2011, volume 71 issue 5, 1805–1815.106
Abbreviations: FL-1H, intensity (height) in the FL-1 channel; FL-2H, intensity (height) in the FL-2 channel; PBS, phosphate buffered saline; SSC-H, side scatter height values.
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Intratumoral injection of EMCV led to rapid regression of 
tumor growth in a murine RCC xenograft model. This study 
provides compelling preclinical evidence for the use of 
EMCV in the treatment of RCC and potentially other tumors 
with elevated HIF and NF-κB-survival signature.
Hypoxic tumor-infiltrating 
macrophages as carrier cells to 
deliver OVs
Macrophages and their precursors in the bloodstream, mono-
cytes, are continually recruited into tumors and migrate into 
avascular hypoxic/necrotic areas.104,105 The fact that tumor-
associated macrophages can infiltrate into hypoxic/necrotic 
areas of tumors prompted investigators to exploit mac-
rophages as a vehicle to deliver HIF-regulated OV and 
therapeutic genes to otherwise inaccessible areas in tumors. 
Earlier this year, Muthana et al described a new cell-based 
method that selectively targets an oncolytic Ad to hypoxic 
areas of prostate tumors using macrophages as carriers.106 
Macrophages were cotransduced with a hypoxia-regulated 
E1A/B construct and an E1A-dependent oncolytic Ad, whose 
replication is restricted to prostate tumor cells. When such 
cotransduced macrophages reach an area of extreme hypoxia, 
the E1A/B proteins are expressed, thereby activating replica-
tion of the Ad. This was indeed the case as demonstrated in 
mice bearing subcutaneous or orthotopic prostate tumors. 
The cotransduced macrophages migrated into hypoxic tumor 
areas, upregulated E1A protein, and released multiple copies 
of progeny Ad. The virus then infected neighboring cells and 
was cytotoxic in prostate tumor cells, resulting in the marked 
inhibition of tumor growth and reduction of pulmonary 
metastases (Figure 1).106
This approach is very innovative and efficacious to 
deliver an oncolytic Ad to hypoxic areas of tumor. However, 
as correctly pointed out by Baas, it remains unclear whether 
relying on hypoxic regulation as the only homing determinant 
will be sufficient to deliver an OV to micrometastatic disease, 
which are much smaller than solid tumors and not overtly 
hypoxic.107 In addition, macrophages may not function 
effectively as carrier cells for other OVs. For example, 
murine primary macrophages are not susceptible to infection 
by an oncolytic poxvirus (Guo et al, unpublished data).
Conclusion
Some OVs adapt to the hypoxic environment better than 
others. Oncolytic HSVs display enhanced replication while 
Ads show reduced replication potency in hypoxic cancer 
cells. Other OVs such as VACV and VSV show similar 
replication efficiency in hypoxic and normoxic conditions. 
Interestingly, VACV-mediated oncolysis is enhanced in some 
hypoxic pancreatic cancer cells even though there was no 
evidence of enhanced viral replication.
Future directions
To further improve oncolytic virotherapy, the underlying 
mechanisms through which hypoxia and an OV interact to 
control life cycles of both host cells and the particular virus in 
tumor cells need to be understood, and consequently the means 
to optimize not only viral production but also the virus-induced 
cytotoxicity in such pathogenic TME need to be developed. 
The mechanistic studies may lead to further understanding of 
regulatory signaling pathways for efficient viral replication, 
eventual oncolysis, and subsequent immunological responses 
to both the tumor antigens and the virus itself. This will lead 
to more effective oncolytic virotherapy. In addition, more 
efficient OVs for hypoxic TME could be obtained via two 
approaches. The first is rational design via genetic engineer-
ing. Alternatively, “directed evolution” methodology may be 
used.29,30 Under this approach, highly diverse viral pools will 
be placed under stringent directed selection to generate and 
identify highly potent agents for hypoxic tumors.
More successful therapeutic regimens for hypoxic tumor 
may lie in the combination of OV with different OVs or 
other proven modalities such as chemotherapy, radiotherapy, 
and/or immunotherapy, which has become a research trend 
for oncolytic virotherapy in the last few years.23,108 The strategy 
of combining oncolytic virotherapy with chemotherapy for 
treating hypoxic areas of cancer is supported by mathematical 
modeling. Owen and colleagues applied mathematical model-
ing and predicted synergistic antitumor effects of combining 
a macrophage-based, hypoxia-targeted gene therapy with 
chemotherapy.109 Oncolytic virotherapy itself has been 
considered to be a type of immunotherapy. Evidence is 
accumulating that it potentially can function synergistically 
with other types of immunotherapy.110–112 The use of carrier 
cells to deliver OVs to hypoxic areas of tumor has shown 
early promise.106 It is worth exploring further the application 
of macrophages and other hypoxic tumor-homing cells as 
carriers for delivering OVs to hypoxic tumor.
An emerging concept in cancer therapy is normaliza-
tion of tumor vasculation as a complementary therapeutic 
paradigm.113,114 Tumor treated with inhibitors that block 
epidermal growth factor receptor, Ras, or phosphati-
dylinositol-3-OH kinase-Akt resulted in prolonged and 
durable enhancement of tumor vascular flow, perfusion, 
and decreased tumor hypoxia.114 It is tempting to think that, 
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following such treatments, even “regular” (not hypoxia-
targeted) OVs could be utilized to treat these preconditioned 
cancers effectively.
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